InvestorsHub Logo
Followers 32
Posts 10384
Boards Moderated 0
Alias Born 04/20/2016

Re: loanranger post# 53604

Saturday, 01/16/2021 1:02:50 PM

Saturday, January 16, 2021 1:02:50 PM

Post# of 54032
Perhaps the Companies resources to implement its agenda are changing.

Has the balance sheet changed due to the use of the Offering and assets appreciating?

Do you think any company stating that they want to improve its Board of Directors is a bad thing’?

I think if there is any chance of the nausea drug succeeding Tauriga must do everything it can to position itself for a future NASDAQ listing.

Look at what just happened to Tauriga’s holding in VTGN. VTGN went from a potential NASDAQ delisting to curing its deficiency for market cap and minimum bid requirement virtually overnight.

In fact, they received a $100 million dollar investment before minimum bid deficiency was cured.

That is how fast circumstances could change in biotech. I have stated for 1 year if Tauriga is to succeed big it will be through a pharma success. Or at least making progress through trial milestones.
Drug trials are difficult. The nausea market is estimated at $7 bil a year. That will be a difficult market to penetrate without a pharma drug partner, at least on the sales and marketing side. But since this is not curing a disease, and only trying to remedy the negative effects from chemotherapy the path to success is slightly easier.

A board with better management would be a good thing going forward.

You should apply?

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.